SCHEMBL72738

SCHEMBL72738

CC(C)(C)OC(=O)N1CCC(Oc2cc(F)ccc2Cl)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 5/20 0.55
SCD O00767 4/20 0.51
PDE4D Q08499 3/20 0.51
PDE4B Q07343 3/20 0.51
PDE4A P27815 2/20 0.51
PDE4C Q08493 2/20 0.51
KDM1A O60341 1/20 0.50
NPBWR1 P48145 1/20 0.48
MCHR1 Q99705 1/20 0.48
CACNB4 O00305 1/20 0.48
CACNA1A O00555 1/20 0.48
CACNA1G O43497 1/20 0.48
CACNG3 O60359 1/20 0.48
CACNA1F O60840 1/20 0.48
CACNA1H O95180 1/20 0.48
CACNB3 P54284 1/20 0.48
CACNA2D1 P54289 1/20 0.48
CACNG7 P62955 1/20 0.48
CACNA1B Q00975 1/20 0.48
CACNA1D Q01668 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4106885 0.91 GPR119 (0.58) GPR119PDE4DPDE4BPDE4APDE4C
SCHEMBL70696 0.88 GPR119 (0.60) GPR119PDE4DPDE4BPDE4APDE4C
SCHEMBL7727287 0.87 NPBWR1 (0.57) GPR119PDE4DPDE4BPDE4APDE4C
SCHEMBL4654918 0.87 GPR119 (0.54) GPR119PDE4DPDE4BPDE4APDE4C
SCHEMBL29716374 0.86 GPR119 (0.56) GPR119SCDPDE4DPDE4BPDE4A
SCHEMBL16280397 0.86 PDE4B (0.51) GPR119PDE4DPDE4BPDE4APDE4C
SCHEMBL2764837 0.86 GPR119 (0.55) GPR119SCDPDE4DPDE4BPDE4A
SCHEMBL27462772 0.86 KDM1A (0.53) GPR119PDE4DPDE4BPDE4APDE4C
SCHEMBL6113438 0.86 GPR119 (0.55) GPR119PDE4DPDE4BPDE4APDE4C
SCHEMBL2776116 0.86 GPR119 (0.69) GPR119PDE4DPDE4BPDE4APDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12268687-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2025-04-08 US disclosed
US-20250034124-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2025-01-30 US disclosed
US-12098146-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-09-24 US disclosed
US-20230116101-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. 2023-04-13 US disclosed
CN-113906019-A Compound and use thereof 优曼尼蒂治疗公司 2022-01-07 CN disclosed
EP-3914593-A1 COMPOUNDS AND USES THEREOF Yumanity Therapeutics, Inc. (US) 2021-12-01 EP disclosed
WO-2021097240-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2021-05-20 WO disclosed
US-20210139471-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2021-05-13 US disclosed
US-20210139471-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2021-05-13 US disclosed
WO-2020154571-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2020-07-30 WO disclosed
WO-2020154571-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2020-07-30 WO disclosed
CN-106470990-A pyridazine compounds 武田药品工业株式会社 2017-03-01 CN disclosed
US-8129376-B2 Piperidine derivatives as inhibitors of stearoyl-CoA desaturase AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-03-06 US disclosed
EP-2268143-A2 NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE Forest Laboratories Holdings Limited (BM) 2011-01-05 EP disclosed
WO-2009117676-A2 NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-24 WO disclosed
US-20090239810-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250034124-A1 COMPOUNDS AND USES THEREOF NLN, BDNF, NQO1 GPR119 3998/4885SCD 3755/4885PDE4D 253/4885
US-12268687-B2 Compounds and uses thereof NLN, BDNF, NQO1 GPR119 3998/4885SCD 3755/4885PDE4D 253/4885
US-20090239810-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE SCD, SCD5, FADS2 GPR119 691/4885SCD 1/4885PDE4D 1857/4885
US-20230116101-A1 COMPOUNDS AND USES THEREOF NLN, BDNF, NQO1 GPR119 3998/4885SCD 3755/4885PDE4D 253/4885
US-20210139471-A1 COMPOUNDS AND USES THEREOF NLN, BDNF, NQO1 GPR119 3998/4885SCD 3755/4885PDE4D 253/4885
US-12098146-B2 Compounds and uses thereof NLN, BDNF, NQO1 GPR119 3998/4885SCD 3755/4885PDE4D 253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.